MA46625B1 - Inhibiteurs de lsd1 et leurs utilisations médicales - Google Patents

Inhibiteurs de lsd1 et leurs utilisations médicales

Info

Publication number
MA46625B1
MA46625B1 MA46625A MA46625A MA46625B1 MA 46625 B1 MA46625 B1 MA 46625B1 MA 46625 A MA46625 A MA 46625A MA 46625 A MA46625 A MA 46625A MA 46625 B1 MA46625 B1 MA 46625B1
Authority
MA
Morocco
Prior art keywords
medical uses
lsd1
lsd1 inhibitors
diseases
formula
Prior art date
Application number
MA46625A
Other languages
English (en)
Other versions
MA46625A (fr
Inventor
Victor Gehling
Francois Brucelle
Avinash Khanna
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Priority claimed from PCT/US2017/058405 external-priority patent/WO2018081343A1/fr
Publication of MA46625A publication Critical patent/MA46625A/fr
Publication of MA46625B1 publication Critical patent/MA46625B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés de formule (i ou ia') et leurs sels pharmaceutiquement acceptables, qui sont utiles pour le traitement de divers troubles, maladies ou états pathologiques, associés à lsd1. L'invention concerne également des compositions pharmaceutiques comprenant les nouveaux composés de formule (i ou ia'), leurs sels pharmaceutiquement acceptables, et leurs procédés d'utilisation dans le traitement d'un ou de plusieurs troubles, maladies ou états pathologiques, associés à lsd1.
MA46625A 2016-10-26 2017-10-26 Inhibiteurs de lsd1 et leurs utilisations médicales MA46625B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662413162P 2016-10-26 2016-10-26
PCT/US2017/058405 WO2018081343A1 (fr) 2016-10-26 2017-10-26 Inhibiteurs de lsd1 et leurs utilisations médicales

Publications (2)

Publication Number Publication Date
MA46625A MA46625A (fr) 2019-09-04
MA46625B1 true MA46625B1 (fr) 2023-11-30

Family

ID=65351698

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46625A MA46625B1 (fr) 2016-10-26 2017-10-26 Inhibiteurs de lsd1 et leurs utilisations médicales

Country Status (2)

Country Link
AR (1) AR109887A1 (fr)
MA (1) MA46625B1 (fr)

Also Published As

Publication number Publication date
MA46625A (fr) 2019-09-04
AR109887A1 (es) 2019-01-30

Similar Documents

Publication Publication Date Title
MA44674A (fr) Inhibiteurs de bromodomaine
MA47043A1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA47079A (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
MX2021004431A (es) Procesos novedosos.
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA41179A (fr) Composés inhibiteurs de parg
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA40290A1 (fr) Agents immunorégulateurs
MA39554A3 (fr) Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock
MA40123A1 (fr) Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA47301B1 (fr) Inhibiteurs sélectifs de jak1
MA54386B1 (fr) Modulateurs de trex1
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA46229A (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA38425B1 (fr) Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA49839B1 (fr) Inhibiteurs bicycliques de la histone déacétylase
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
MA46625B1 (fr) Inhibiteurs de lsd1 et leurs utilisations médicales
MA39533A1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives